



(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 37/06* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/IB2022/000443

(22) International Filing Date:
02 August 2022 (02.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/203,856 02 August 2021 (02.08.2021) US

(71) Applicant: **ARGENX BV** [BE/BE]; Industriepark Zwij-
naarde 7, 9052 Ghent (BE).

(72) Inventors: **VAN BRAGT, Antoinetta Jacoba Maria**; c/o
Argenx BV, Industriepark Zwijnaarde 7, 9052 Ghent (BE).
ULRICHTS, Peter; c/o Argenx BV, Industriepark Zwij-
naarde 7, 9052 Ghent (BE). **HOFMAN, Erik**; c/o Argenx
BV, Industriepark Zwijnaarde 7, 9052 Ghent (BE). **VER-
HEESEN, Peter**; c/o Argenx BV, Industriepark Zwijnaarde
7, 9052 Ghent (BE).


(74) Agent: **BOULT WADE TENNANT LLP** (ASSOC. NO.
505); Salisbury Square House, 8 Salisbury Square, London
EC4Y 8AP (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SUBCUTANEOUS UNIT DOSAGE FORMS

FIGURE 1



(57) Abstract: Provided herein are unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

06 April 2023 (06.04.2023)